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ABSTRACT
Background: β-blockers (BBs) are considered primary therapy in stable heart failure (HF) 
with reduced ejection fraction (HFrEF) without atrial fibrillation (AF); evidence-based 
benefits of BB on outcome have been documented. However, BBs have not been shown to 
improve mortality or reduce hospital admissions in HF patients with AF. This study assessed 
the relationship between BBs at discharge and relevant clinical outcomes in acute heart 
failure (AHF) patients with AF.
Methods: From the Korean Acute Heart Failure Registry, 936 HFrEF and 639 HF patients with 
preserved ejection fraction (HFpEF) and AF were selected. Propensity score (PS) matching 
accounted for BB selection bias when assessing associations.
Results: BB-untreated patients in the overall cohort of HFrEF and HFpEF had greater 
deteriorated clinical and laboratory characteristics. In the 670 PS-matched cohort of HFrEF 
patients, incidences of all clinical events at 60 days and 1 year were not different according to 
use of BBs. In the 470 PS-matched cohort of HFpEF, rehospitalization and composite outcome 
at 6 months and 1 year more frequently occurred in non-users of BBs. After adjusting for 
covariates in the multivariable Cox model of matched cohorts, BB was not associated with 
clinical outcomes at 60 days and 1 year in HFrEF with AF patients. In HFpEF patients with AF, 
BB use was associated with reduced 6-month (hazard ratio [HR], 0.38; 95% confidence interval 
[CI], 0.20–0.74) and 1-year rehospitalization (HR, 0.53; 95% CI, 0.34–0.82).
Conclusion: In the HFrEF with AF PS-matched cohort, the use of BBs at discharge was not 
associated with clinical outcome. However, in HFpEF with AF, the use of BB was associated 
with reduced rehospitalization during the 6-month and 1-year follow up.
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INTRODUCTION
β-blockers (BBs) constitute a cornerstone of therapy in patients with chronic heart failure 
(HF) with reduced ejection fraction (HFrEF) based on the results of landmark trials.1,2 
According to both European and American guidelines, the use of BBs in symptomatic 
patients with HFrEF has a class 1A recommendation.1,2 Nonetheless, there is a suboptimal 
utilization of recommended medications in patients at the greatest risk of death who are least 
likely to receive evidence-based therapy.3 BBs have not been fully evaluated in clinical trials, 
and there have been concerns regarding treatment efficacy, particularly in patients with acute 
decompensated HF, atrial fibrillation (AF), and HF with preserved ejection fraction.
Acute heart failure (AHF) is a life-threatening medical condition with high inpatient mortality 
(typically > 4%).4 However, evidence supporting the benefits of BB treatment (reduced 
mortality) in AHF is lacking and there are concerns about the negative inotropic effects of BBs; 
thus, the potential worsening of hemodynamics leads many physicians to stop BB treatment in 
AHF. The same concern about the beneficial effect of BB has been conclusively demonstrated 
to be inappropriate with regard to chronic HF management.5-7 On the other hand, AF is 
common in patients with HF because the pathophysiology and risk factors for HF and AF are 
closely associated.8 Furthermore, patients with concomitant HF and AF have significantly 
poorer prognoses.9 Although BBs are widely used in AF with and without HF as first-line 
control therapy, a recently performed meta-analysis of key BB randomized control trials (RCTs) 
involving chronic stable HFrEF patients showed that BBs were not effective in reducing all-
cause mortality in patients with AF, but were effective in patients with normal sinus rhythm 
(NSR).10-12 In addition, no treatment to date has convincingly reduced morbidity or mortality in 
patients with HF with preserved ejection fraction (HFpEF) especially when combined with AF.13 
Previous analyses in these patient subsets have lacked statistical power. Thus, the present study 
assessed whether BBs prescribed at discharge could improve prognosis in AHF patients with AF 
in a large nationwide prospective cohort.
METHODS
Study population
The Korean Acute Heart Failure (KorAHF) study is a multicenter prospective cohort study that 
enrolled 5,625 consecutive patients who were hospitalized for AHF at 10 tertiary university 
hospitals between March 2011 and February 2014. Detailed information on the study design 
and the results of the KorAHF registry has been provided previously.14 Briefly, the registry 
included patients with signs or symptoms of HF who met at least one of the following 
criteria: 1) lung congestion or 2) objective findings of left ventricular (LV) dysfunction or 
structural heart disease. From this population, we selected patients with HF and AF who had 
survived hospitalization with available 1-year follow-up data.
Study variables and clinical outcomes
HFrEF was defined as left ventricular ejection fraction (LVEF) < 40% and HFpEF as LVEF 
≥ 50%.2 AF was confirmed with 12-lead electrocardiography at admission or during 
hospitalization. Patients who received only guideline-recommended BBs, including 
bisoprolol, carvedilol, sustained-release metoprolol succinate, and nebivolol at discharge, 
were considered as BB-treated.1,2 Patients not eligible for BB therapy whose systolic 
blood pressure was < 90 mmHg or resting heart rate was < 50 bpm at discharge were 
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excluded.2 In this study, the outcomes were defined as 60-day and 1-year all-cause mortality, 
rehospitalization because of aggravated HF, and a composite endpoint of mortality and HF 
rehospitalization. The attending physician collected follow-up data through a web-based case 
report form. The outcome data for subjects who were not followed up were ascertained by a 
telephone interview and confirmed from the National Death Records. All clinical events were 
monitored and verified by a Clinical Event Committee, comprising independent experts on 
HF who did not participate in patient enrollment for the study.14
Statistical analysis
Statistical analyses were conducted by the Center of Biomedical Data Science, Yonsei 
University, Wonju College of Medicine. Propensity score (PS) analysis was used to account 
for selection bias of BB prescription when assessing the association. The variables selected 
for the score were age, sex, body mass index, systolic blood pressure, heart rate at admission, 
history of hypertension, ischemic heart disease, chronic lung disease, chronic kidney disease, 
LVEF and other discharge medications including angiotensin converting enzyme inhibitor 
(ACEi), angiotensin-receptor II blocker (ARB), mineralocorticoid receptor antagonists 
(MRA), and anticoagulants. BB-treated and -untreated patients were then matched 1:1 using 
the nearest neighbor method with caliper < 0.01 and no replacement. Continuous variables 
were reported as mean ± standard deviation and were compared with the independent t-test. 
Categorical variables were presented as frequencies and percentages and were compared 
using the χ2 test. Individual and composite clinical outcomes were analyzed based on time 
to the first event. Kaplan-Meier survival curves were plotted, and the groups were compared 
using the log-rank test. To assess the relationship between outcomes and use of BBs, Cox 
proportional hazards regression models were used and adjusted for sex, age, history of 
hypertension, diabetes mellitus, ischemic heart disease, chronic obstructive pulmonary 
disease, and systolic blood pressure. The models also adjusted for heart rate, serum sodium 
levels, hemoglobin levels, creatinine levels, LVEF, discharge medication including ACEi 
or ARB, MRA and anticoagulation in the matching cohort. The proportional hazards 
assumption was confirmed using log (-log) survival plots and time interaction terms. In 
all cases, a P value < 0.05 was considered statistically significant. Statistical analyses were 
performed using SPSS Version 23.0 (IBM, Armonk, NY, USA).
Ethics statement
The study protocol was approved by the Institutional Review Boarad at each hospital and 
the Wonju Christian Hospital, Wonju College of Medicine, Yonsei University (Approval No. 
CR311003), and written informed consent was obtained from each patient or their relative or 
legal representative.
RESULTS
The number of AF patients eligible for BB therapy was 1,946 out of the 5,625 patients in the 
KorAHF registry. In addition, among these HF patients with AF, 936 were diagnosed HFrEF and 
639 were HFpEF. BB was used in 543 (58%) patients with HFrEF and in 249 (40.0%) with HFpEF. 
After PS matching, the analysis was restricted to 1,140 patients: 670 HFrEF and 470 HFpEF.
Baseline characteristics and medication at discharge of HFrEF and AF
In HFrEF patients with AF, the median age of the cohort was 71 (interquartile range [IQR], 
61–78) years and 62.1% were males. BB-treated and BB-untreated patients differed with regard 
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to most of the baseline characteristics (Table 1). Patients who did not receive BBs were older, 
had a lower body mass index and diastolic blood pressure, different pattern of comorbidities 
(more likely chronic kidney disease and obstructive pulmonary disease), different etiology of 
HF, and laboratory characteristics (lower levels of sodium and hemoglobin and lower ejection 
fraction). At discharge, other pharmacological therapies including ACEi and MRA were less 
frequently prescribed in BB-untreated patients (Supplementary Table 1). After PS matching, 
there were no statistically significant differences in baseline characteristics between BB-
treated and BB-untreated patients, except in left bundle branch on the electrocardiogram and 
serum sodium levels (Table 1).
Baseline characteristics and medication at discharge of patients with HFpEF 
and AF
In HFpEF patients with AF, the median age of the cohort was 76 (IQR, 69–82) years and 
36.8% were males. BB-untreated patients differed from the treated patients with regard to 
most of the baseline characteristics, as described in HFrEF (Table 2). BB-untreated patients 
had lower diastolic blood pressure, more likely hypertension, different etiologies of HF, 
and laboratory characteristics (lower levels of sodium, hemoglobin, left atrial dimension, 
and higher prevalence of left bundle branch block). At discharge, the prescription rate of 
other medication was not different between the groups (Supplementary Table 2). After 
PS matching, there were no statistically significant differences in baseline characteristics 
between BB-treated and BB-untreated patients, except in the etiology of HF and prevalence of 
left bundle branch block (Table 2).
Association between BB use and outcomes for patients with HFrEF and AF
At discharge in the matched cohort, the heart rate was significantly lower in BB-treated 
patients (75.3 ± 14.4 bpm vs. 78.5 ± 13.7 bpm, P < 0.01) and systolic blood pressure at 1-year 
follow up was lower in BB-treated patients (113.5 ± 16.4 mmHg vs. 117.6 ± 16.6 mmHg, P < 0.01) 
(Supplementary Table 3). In the overall cohort of HFrEF patients, 187 (20%) patients died from 
any cause and 184 (19.7%) were hospitalized due to worsening HF. All clinical events occurred 
more frequently in BB-untreated patients except 60-day rehospitalization (Supplementary 
Table 4); however, after PS matching, there was no difference in clinical outcomes 
(Supplementary Table 4). Event-free survival was not different according to the use of BB 
(Fig. 1), and after adjusting for covariates in the multivariable Cox model of matching cohort, 
there was no association between BB treatment and all clinical outcomes at the 60-day and 
1-year follow up (Fig. 2). This statistical significance did not change after including digoxin 
and amiodarone at discharge as covariates (Supplementary Table 5).
In an exploratory subgroup analysis for 1-year rehospitalization and mortality, no significant 
interactions were observed at clinical cutoffs for variables, including age, sex, history of 
hypertension, diabetes mellitus, ischemic heart disease, myocardial infarction, chronic 
obstructive lung disease, type of HF, heart rate at admission and at discharge, as well as 
concomitant use of digoxin and amiodarone. However, in the subgroup of patients who had 
a history of myocardial infarction, the rate of rehospitalization (HR, 0.34; 95% CI, 0.13–0.88) 
and mortality (HR, 0.17; 95% CI, 0.06–0.49) was significantly lower in BB treated patients 
(Supplementary Fig. 1).
Association between BB use and outcomes for patients with HFpEF and AF
Heart rate was significantly lower in BB-treated patients at discharge and 1-year follow up 
(74.9 ± 13.1 bpm vs. 79.0 ± 13.9 bpm, P = 0.001) (76.7 ± 15.9 bpm vs. 82.5 ± 19.4 bpm, P = 0.01) 
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Table 1. Baseline characteristics of patients with heart failure with reduced ejection fraction and atrial fibrillation according to the use of β-blockers
Characteristics Overall cohort Matched cohort
BB treated  
(n = 543)
BB untreated  
(n = 393)
P value BB treated  
(n = 335)
BB untreated  
(n = 335)
P value Standardized 
difference, %
Demographic characteristic
Male 342 (63.0) 239 (60.8) 0.500 205 (61.2) 197 (58.8) 0.528 4.87
Age, yr 67.5 ± 13.2 70.5 ± 12.6 0.001 69.8 ± 12.1 69.8 ± 12.5 0.997 0.02
Height, cm 163.2 ± 9.3 161.7 ± 9.7 0.018 162.5 ± 9.3 161.6 ± 9.6 0.237 9.19
Weight, cm 63.4 ± 13.6 59.8 ± 12.5 < 0.001 61.2 ± 11.8 60.4 ± 12.8 0.423 6.21
BMI, kg/m2 23.6 ± 3.8 22.8 ± 3.7 < 0.001 23.1 ± 3.5 23.0 ± 3.8 0.784 8.30
sBP, mmHg 127.7 ± 27.1 126.0 ± 27.4 0.339 126.3 ± 26.4 127.3 ± 27.6 0.614 −3.91
dBP, mmHg 81.0 ± 19.1 77.8 ± 16.7 0.008 79.5 ± 18.8 78.6 ± 17.0 0.511 5.10
Heart rate, beat/min 99.0 ± 28.7 101.3 ± 29.5 0.225 100.8 ± 30.1 101.3 ± 29.6 0.832 −1.65
NYHA functional class 0.226 0.162 −5.09
Class II 70 (12.9) 51 (13.0) 42 (12.5) 48 (14.3)
Class III 228 (42.0) 144 (36.6) 141 (42.1) 117 (34.9)
Class IV 245 (45.1) 198 (50.4) 152 (45.4) 170 (50.7)
De novo heart failure 280 (51.6) 156 (39.7) < 0.001 163 (48.7) 137 (40.9) 0.043 −15.63
Comorbidity
Hypertension 309 (56.9) 207 (52.7) 0.199 184 (54.9) 182 (54.3) 0.877 −1.20
DM 176 (32.4) 107 (27.2) 0.088 108 (32.2) 92 (27.5) 0.177 −10.44
IHD 127 (23.5) 95 (24.2) 0.817 79 (23.7) 82 (24.5) 0.803 1.93
MI 84 (15.6) 51 (13.0) 0.269 53 (15.9) 43 (12.8) 0.263 −11.24
CKD 54 (9.9) 65 (16.5) 0.003 44 (13.1) 40 (11.9) 0.641 −3.60
COPD 55 (10.1) 58 (14.8) 0.032 45 (13.4) 45 (13.4) 1.000 0.00
Medication at admission
ACEi 89 (12.7) 62 (15.8) 0.182 36 (10.7) 55 (16.4) 0.032 16.59
ARB 137 (25.2) 111 (28.2) 0.302 81 (24.2) 97 (29.0) 0.162 10.81
BBs 197 (36.3) 72 (18.3) < 0.001 126 (37.6) 63 (18.8) < 0.001 −42.67
MRA 110 (20.3) 91 (23.2) 0.287 72 (21.5) 79 (23.6) 0.517 5.00
Etiology of heart failure 0.038 0.380 9.18
IHD 146 (26.9) 123 (31.3) 95 (28.4) 103 (30.7)
VHD 50 (9.2) 65 (16.5) 37 (11.0) 54 (16.1)
Cardiomyopathy 166 (30.6) 97 (24.7) 101 (30.1) 81 (24.2)
HHD 12 (2.2) 5 (1.3) 5 (1.5) 4 (1.2)
Tachycardia induced 127 (23.4) 78 (19.8) 77 (23.0) 73 (21.8)
ECG characteristics at admission
LBBB 38 (7.0) 16 (4.1) 0.058 29 (8.7) 14 (4.2) 0.018 −18.32
RBBB 31 (5.7) 29 (7.4) 0.303 18 (5.4) 23 (6.9) 0.420 6.22
Laboratory characteristics at admission
Na+, mmol/L 138.1 ± 4.1 136.9 ± 5.2 < 0.001 137.7 ± 4.2 136.9 ± 5.4 0.024 17.55
K+, mmol/L 4.4 ± 0.7 4.4 ± 0.6 0.047 4.4 ± 0.7 4.4 ± 0.6 0.648 −3.53
Albumin, g/dL 3.7 ± 0.4 3.7 ± 0.5 0.576 3.7 ± 0.5 3.7 ± 0.4 0.797 2.00
Hemoglobin, g/dL 13.2 ± 2.3 12.8 ± 2.2 0.011 13.0 ± 2.3 12.9 ± 2.2 0.588 4.19
Creatinine, mg/dL 1.4 ± 1.2 1.5 ± 1.4 0.280 1.5 ± 1.3 1.4 ± 1.3 0.418 6.26
hs-CRP, mg/dL 1.9 ± 2.9 2.2 ± 4.0 0.390 1.9 ± 3.0 2.2 ± 4.0 0.519 −7.58
NT-proBNP, pg/mL 9,562.4 ± 9,961.5 1,157.7 ± 11,488.5 0.091 10,573.6 ± 10,200.7 10,348.6 ± 11,137.3 0.837 2.11
BNP, pg/mL 1,360.1 ± 1,376.1 1,493.0 ± 1,142.8 0.393 1,412.9 ± 1,470.7 1,425.8 ± 1,229.3 0.942 −0.95
CK-MB, ng/mL 5.5 ± 12.9 7.4 ± 22.3 0.114 5.3 ± 10.4 7.3 ± 22.7 0.180 −10.97
Troponin I, mg/mL 0.8 ± 3.6 1.6 ± 8.3 0.092 0.8 ± 3.9 1.7 ± 8.9 0.142 −12.76
Echocardiographic characteristics
LVEF, % 27.7 ± 8.1 26.6 ± 8.2 0.041 27.1 ± 7.9 27.1 ± 7.9 0.935 −0.63
LVEDV, mL 159.1 ± 67.8 166.1 ± 72.4 0.192 158.6 ± 70.2 165.7 ± 70.4 0.266 −9.99
LVESV, mL 115.5 ± 55.4 119.5 ± 57.9 0.354 116.0 ± 57.9 118.8 ± 55.7 0.589 −4.85
LA dimension, mm 50.7 ± 8.0 51.9 ± 10.8 0.063 50.6 ± 7.7 51.9 ± 10.6 0.097 −13.02
Values are presented as numbers (%) or mean ± standard deviation. unless otherwise indicated.
BBs = β-blockers, BMI = indicates body mass index, sBP = systolic blood pressure, dBP = diastolic blood pressure, NYHA = New York Heart Association, DM = 
diabetes mellitus, IHD = ischemic heart disease, MI = myocardial infarction, CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease, ACEi 
= angiotensin converting enzyme inhibitor, ARB = angiotensin-receptor II blocker, MRA = mineralocorticoid receptor antagonists, VHD = valvular heart disease, 
HHD = hypertensive heart disease, ECG = electrocardiography, LBBB = left bundle branch block, RBBB = right bundle branch block, hs-CRP = high-sensitivity 
C-reactive protein, NT-proBNP = N-terminal pro-brain natriuretic peptide, BNP = B-type natriuretic peptide, CK-MB = Creatine kinase-MB, LVEF = left ventricular 
ejection fraction, LVEDV = left ventricular end-diastolic volume, LVESV = left ventricular end-systolic volume, LA = left atrium.
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Table 2. Baseline characteristics of patients with heart failure with preserved ejection fraction and atrial fibrillation according to the use of β-blockers
Characteristics Overall cohort Matched cohort
BB treated  
(n = 249)
BB untreated  
(n = 390)
P value BB treated  
(n = 235)
BB untreated  
(n = 235)
P value Standardized 
difference, %
Demographic characteristic at admission
Male 93 (37.3) 142 (36.4) 0.810 83 (35.3) 84 (35.7) 0.923 −0.89
Age, yr 73.8 ± 11.3 73.7 ± 12.1 0.934 73.8 ± 11.5 74.3 ± 12.2 0.683 −3.77
Height, cm 157.6 ± 8.6 157.4 ± 9.5 0.859 157.3 ± 8.5 157.2 ± 9.5 0.970 0.35
Weight, cm 59.1 ± 12.2 58.5 ± 12.4 0.540 58.9 ± 12.3 58.8 ± 12.6 0.918 0.95
BMI, kg/m2 23.7 ± 4.0 23.5 ± 4.2 0.587 23.7 ± 4.0 23.7 ± 4.1 0.931 0.80
sBP, mmHg 134.9 ± 28.2 133.3 ± 27.7 0.474 135.5 ± 28.2 135.6 ± 28.6 0.960 −0.47
dBP, mmHg 81.36 ± 18.6 77.8 ± 19.0 0.014 81.8 ± 18.5 80.2 ± 19.3 0.358 8.50
Heart rate, beat/min 94.2 ± 26.9 90.8 ± 28.6 0.136 93.1 ± 25.7 94.4 ± 29.7 0.595 −4.92
NYHA functional class 0.746 0.920 −2.27
Class II 44 (17.7) 74 (19.0) 42 (17.9) 42 (17.9)
Class III 94 (37.8) 154 (39.5) 88 (37.4) 84 (35.7)
Class IV 111 (44.6) 162 (41.5) 105 (44.7) 109 (46.4)
De novo heart failure 135 (54.2) 172 (44.1) 0.013 129 (54.9) 109 (46.4) 0.065 −17.05
Comorbidity
Hypertension 189 (75.9) 240 (61.5) < 0.001 176 (74.9) 169 (71.69) 0.465 −6.73
DM 81 (32.5) 103 (26.4) 0.096 77 (32.8) 67 (28.5) 0.317 −9.22
IHD 42 (16.9) 71 (18.2) 0.666 40 (17.0) 31 (13.2) 0.246 −10.69
MI 18 (7.2) 24 (6.2) 0.593 17 (7.2) 7 (3.0) 0.036 −19.38
CKD 24 (9.6) 32 (8.2) 0.532 21 (8.9) 23 (9.8) 0.751 2.92
COPD 28 (11.2) 60 (15.4) 0.139 26 (11.1) 27 (11.5) 0.884 1.34
Medication at admission
ACEi 15 (6.0) 26 (6.7) 0.746 15 (6.4) 21 (8.9) 0.298 9.59
ARB 78 (31.3) 132 (33.8) 0.508 67 (28.5) 80 (34.0) 0.196 11.93
BB 134 (53.8) 86 (22.1) < 0.001 123 (52.3) 51 (21.7) < 0.001 −66.77
MRA 41 (16.5) 98 (25.1) 0.010 41 (17.4) 47 (20.0) 0.480 6.53
Etiology of heart failure < 0.001 0.001 13.34
IHD 47 (18.9) 43 (11.0) 46 (19.6) 24 (10.2)
VHD 62 (24.9) 171 (43.8) 60 (25.5) 106 (45.1)
Cardiomyopathy 20 (8.0) 21 (5.4) 18 (7.7) 14 (6.0)
HHD 7 (2.8) 12 (3.1) 6 (2.6) 8 (3.4)
Tachycardia induced 85 (34.1) 87 (22.3) 77 (32.8) 53 (22.6)
ECG characteristics at admission
LBBB 0 (0.0) 6 (1.5) 0.049 0 (0.0) 4 (1.7) 0.045 18.57
RBBB 15 (6.0) 33 (8.5) 0.254 15 (6.4) 12 (5.1) 0.552 −5.48
Laboratory characteristics at admission
Na+, mmol/L 138.0 ± 4.6 136.7 ± 5.8 0.005 137.9 ± 4.6 136.9 ± 5.6 0.029 20.25
K+, mmol/L 4.3 ± 0.6 4.3 ± 0.7 0.835 4.3 ± 0.6 4.3 ± 0.7 0.561 −5.37
Albumin, g/dL 3.8 ± 0.5 3.7 ± 0.5 0.150 3.8 ± 0.5 3.7 ± 0.5 0.088 15.84
Hemoglobin, g/dL 12.4 ± 1.9 12.0 ± 2.1 0.018 12.3 ± 1.9 12.1 ± 2.1 0.126 14.16
Creatinine, mg/dL 1.1 ± 0.7 1.2 ± 0.7 0.290 1.1 ± 0.7 1.2 ± 0.7 0.251 −10.61
hs-CRP, mg/dL 1.8 ± 3.2 2.0 ± 4.1 0.640 1.8 ± 3.3 2.0 ± 4.0 0.660 −5.42
NT-proBNP, pg/mL 5,976.3 ± 7,129.0 5,595.2 ± 7,071.0 0.637 6,034.8 ± 7,200.7 5,788.9 ± 7,378.0 0.799 3.37
BNP, pg/mL 815.7 ± 682.6 760.0 ± 926.2 0.575 820.5 ± 694.7 747.2 ± 687.2 0.446 10.60
CK-MB, ng/mL 5.0 ± 14.9 6.6 ± 33.7 0.505 5.2 ± 15.3 4.3 ± 10.3 0.483 6.90
Troponin I, mg/mL 1.0 ± 4.3 1.3 ± 10.9 0.709 1.1 ± 4.5 0.5 ± 2.6 0.146 15.14
Echocardiographic characteristics
LVEF, % 58.6 ± 6.5 58.4 ± 6.0 0.674 58.5 ± 6.4 58.5 ± 6.2 0.967 −0.38
LVEDV, mL 99.1 ± 46.4 106.1 ± 44.2 0.395 100.3 ± 47.1 106.1 ± 46.0 0.606 −5.99
LVESV, mL 31.7 ± 5.8 32.3 ± 5.9 0.696 42.5 ± 25.5 43.8 ± 24.4 0.680 −4.80
LA dimension, mm 52.3 ± 9.0 54.6 ± 12.2 0.013 52.6 ± 9.0 54.3 ± 11.8 0.088 −15.96
Values are presented as numbers (%) or mean ± standard deviation, unless otherwise indicated.
BB = β-blockers, BMI = indicates body mass index, sBP = systolic blood pressure, dBP = diastolic blood pressure, NYHA = New York Heart Association, DM = 
diabetes mellitus, IHD = ischemic heart disease, MI = myocardial infarction, CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease, ACEi 
= angiotensin converting enzyme inhibitor, ARB = angiotensin-receptor II blocker, MRA = mineralocorticoid receptor antagonists, VHD = valvular heart disease, 
HHD = hypertensive heart disease, ECG = electrocardiography, LBBB = left bundle branch block, RBBB = right bundle branch block, hs-CRP = high-sensitivity 
C-reactive protein, NT-proBNP = N-terminal pro-brain natriuretic peptide, BNP = B-type natriuretic peptide, CK-MB = Creatine kinase-MB, LVEF = left ventricular 
ejection fraction, LVEDV = left ventricular end-diastolic volume, LVESV = left ventricular end-systolic volume, LA = left atrium.
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Log rank P = 0.10
Fig. 1. Sixty-day and 1-year event-free survival according to treatment with β-blockers in heart failure with reduced ejection fraction. (A) Heart failure 
hospitalization, (B) mortality, (C) composite endpoint at 60-day and (D-F) at 1 year (β-blocker treated, dotted line: β-blocker untreated).
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Fig. 2. Forest plot of clinical outcomes of the β-blocker-treated group compared to those of the untreated group. 
HR = hazard ratio, CI = confidence interval, HFrEF = heart failure with reduced ejection fraction, AF = atrial fibrillation.
(Supplementary Table 3). In the overall cohort of HFpEF patients, 123 (19.2%) patients died 
and 123 (19.2%) were rehospitalized. BB-untreated patients were more frequently hospitalized 
at the 60-day (12.3% vs. 5.2%, P < 0.01) and 1-year follow up (13.3% vs. 23.1%, P < 0.01), 
but mortality was not different (Supplementary Table 6). In addition, the 60-day and 1-year 
rehospitalization free survival rates were more favorable in BB-treated patients (Fig. 3). After 
PS matching, the higher occurrence of 6-month and 1-year rehospitalization in BB-untreated 
patients was also confirmed (Supplementary Table 6), while rehospitalization-free survival 
during the 6-month and 1-year follow-up was higher in BB users (Fig. 2). Furthermore, in 
the multivariable Cox model of the PS-matched cohort, BB use was associated with reduced 
6-month (HR, 0.38; 95% CI, 0.20–0.74) and 1-year rehospitalization (HR, 0.53; 95% CI, 
0.34–0.82). Because of reduced rehospitalization, BB use was associated with reduction of 
6-month and 1-year composite endpoint (Fig. 2). This statistical significance also did not 
change after including digoxin and amiodarone at discharge as covariates (Supplementary 
Table 5). In a subgroup analysis for 1-year rehospitalization, there was significant interaction 
in patients with concomitant use of digoxin (P for interaction = 0.03). For 1-year mortality, 
significant interaction was observed for age (P for interaction = 0.03) (Supplementary Fig. 2).
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Log rank P = 0.001
Fig. 3. Sixty-day and 1-year event-free survival according to the treatment of β-blocker in heart failure with preserved ejection fraction. (A) heart failure 
hospitalization, (B) mortality, (C) composite endpoint at 60-day and (D-F) at 1 year (β-blocker treated, dotted line: β-blocker untreated).
DISCUSSION
Our analysis showed that there was no significant implication of BB on 60-day and 1-year 
clinical outcomes in HFrEF patients with AF. However, the use of BB in HFpEF with AF was 
associated with reduced rehospitalization rates at 6- month and 1-year follow up.
BBs and outcomes in HFrEF with AF
Evidence-based benefits, including reduced ejection fraction (HFrEF) and NSR, of guideline-
directed therapy for HF have been documented but there are limited and conflicting data 
regarding the prognostic implications of guideline-directed therapy for HFrEF patients with 
AF. In our previous study, a higher level of adherence to guidelines was associated with better 
60-day and 1-year prognoses in HFrEF patients with AF.15 The current guideline recommends 
BBs as a cornerstone therapy of HFrEF and it is based on clinical trials that demonstrated an 
improvement in clinical outcomes in HF patients. However, RCTs examining the efficacy of 
BBs in HF patients with concomitant AF, especially patients admitted to hospital with AHF, 
are scarce. Meta-analysis studies and cohort data have reported the efficacy of BBs in HFrEF 
patients with AF but results are conflicting. A recent meta-analysis evaluating the use of BBs 
in HFrEF patients with AF documented that BBs did not reduce mortality in HF patients with 
AF.11,12,16 Additionally, in a meta-analysis of four RCTs evaluating HFrEF with AF, BB showed 
reduced mortality in NSR (HR, 0.63; 95% CI, 0.54–0.73; P < 0.001), but did not reduce 
mortality in AF patients (HR, 0.86; 95% CI, 0.66–1.13; P = 0.28).11 In another meta-analysis 
using individual-patient data, BB therapy did not lead to a significant reduction in all-cause 
mortality in patients with AF (HR, 0.97; 95% CI, 0.83–1.14; P = 0.73).12 In contrast to these 
meta-analyses, cohort studies have reported positive results for BBs. In the report from the 
Swedish Heart Failure Registry, BBs showed a protective effect on mortality (HR, 0.71; 95% 
CI, 0.61–0.84; P < 0.001).17 In the Danish nationwide cohort, evidence of a lower mortality 
with BB therapy was observed in the PS-matched analysis (HR, 0.75; 95% CI, 0.71–0.79).18
Although the exact reason is not clear in this study, there are several possible explanations 
for the conflicting results of the effects of BB therapy in HFrEF patients with AF. First, there 
are several mechanisms for the beneficial effects of BBs. One of the most important is the 
reduction of the heart rate and not a blockage of central sympathetic outflow.19 In HFrEF with 
NSR, lower heart rate has a better outcome with or without BBs.16,20 However, heart rate has 
no prognostic implications in patients with AF.16,20 Patients with AF may need a higher heart 
rate to maintain a similar cardiac output; higher heart rate might be needed during HF. Further, 
a low heart rate in AF may be an expression of an underlying conduction disorder, which itself 
may be associated with impaired outcome.11 Second, AF in patients with HF may be a marker of 
a poorer clinical condition, leading to a worse outcome that is less modifiable by BB therapy.21
BB and outcomes in HFpEF with AF
Evidence that BBs improve symptoms is conflicting in HFpEF patients even with NSR.13 
In a recent individual patient meta-analysis, BBs were effective in HFrEF but not in HFpEF 
patients with NSR or AF.22 Though the exact mechanism for the lack of positive prognostic 
effect of BBs in patients with HFpEF is not known, there is a possible explanation. In the 
pathophysiological view, the beneficial effect of BBs is mediated by a reduction of the resting 
heart rate in NSR. The hemodynamic effects of acute change of heart rate in patients with 
HFpEF have been reported to be different compared with those in patients with normal 
ventricular function.23 Increasing heart rate decreased LV end-diastolic pressure strikingly, 
while end-diastolic, end-systolic, and stroke volumes all declined. These hemodynamic 
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effects were similar in the groups with and without BBs.23 Further, because LV end-diastolic 
pressure declines substantially with heart rate elevations in HFpEF, it is likely that slowing the 
resting heart rate will raise filling pressures. Because increases in the heart rate in patients 
with HFpEF were associated with LV volume reductions that resulted in a blunted heart rate—
cardiac output relationship, slowing of the resting heart rate may modestly reduce the cardiac 
output. This, along with increased filling pressures, is obviously undesirable in patients with 
HFpEF and suggests that higher resting heart rate provides hemodynamic benefits.24 No 
study has been conducted on chronic resting heart rate elevation in HFpEF. In the RACE II 
trial (Rate Control Efficacy in Permanent Atrial Fibrillation: a Comparison Between Lenient 
Versus Strict Rate Control II) including a high proportion of cases with hypertensive heart 
disease and diastolic dysfunction, a more lenient heart rate control strategy of up to 110 per 
minutes was non-inferior to strict control strategy.25 This could provide the clue that different 
significance of HR in HFpEF especially combined with AF.
However, there were some studies reporting contradictory results for the association between 
heart rate and prognosis in HFpEF. The data from the OPTIMIZE-HF (Organized Program to 
Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) registry reported that 
heart rate <70 beats/min was also associated with a lower risk for the combined endpoint of 
HF readmission or all-cause mortality (HR, 0.90; 95% CI, 0.84–0.96; P = 0.002).26 Recently 
the data based on the Swedish Heart Failure Registry demonstrated that higher heart rate was 
associated with increased mortality during the initial years of follow-up in HFpEF with AF.27 
In a large-scale cohort study, BB was associated with reduced mortality (HR, 0.93; 95% CI, 
0.86–0.996; P = 0.04).28 Although the exact reason is not clear in this study, BB was associated 
with reduced 6-month and 1-year rehospitalization. There can be several hypotheses. First, 
HFpEF might be over diagnosed in patients with HFpEF and AF because symptoms might 
reflect AF alone. BBs could have reduced symptoms associated with AF and this could give rise 
to reduction in rehospitalization. Second, heart rate reduction with BBs in HFpEF with AF could 
have prevented tachycardia-induced HF and rehospitalization. In this study, heart rate was 
lower in the BB-treated group during follow up (Supplementary Table 3).
Several limitations of the present study should be noted and caution is needed in the 
interpretation. First, because the sample size was relatively small, this study might be 
underpowered. There is the possibility of a type II error, especially in HF rehospitalization, 
because the survival curves of patients with HFrEF, especially rehospitalization, diverge. We 
calculated the power for rehospitalization outcome in HFrEF patients. A two-sided test of 
whether the HR was one with an overall sample size of 748 subjects (of which 335 are in the 
control group and 335 are in the treatment group) achieved 32% power at a 0.050 significance 
level when the HR was actually 0.699. It was anticipated that proportions of subjects having 
the event during the study should be 0.123 for the control group and 0.087 for the treatment 
group. This study was not powered to investigate several outcomes, especially the influence of 
BB on rehospitalization. Thus, the present findings might be due to a Type II error. Second, 
subgroup analysis had many limitations because of the small sample size. In the report from 
the Swedish Heart Failure Registry, heart rate >100 beats per minute was associated with an 
increased mortality in HFrEF with AF.17 In this study, the number of patients with heart rate > 
100 beats per minute on discharge was small; hence, subgroup analysis for the patients with 
a high heart rate could not be performed. In addition, BB has more pronounced prognostic 
implication in patients with a history of myocardial infarction. However, the number of 
patients with a history of myocardial infarction was very small in patients with HFpEF and AF; 
therefore, subgroup analysis was not possible in these patients. In the myocardial infarction 
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and ischemic heart disease subgroup, the insignificant interaction for 1-year mortality 
might also be caused by the small sample size. Third, this observational cohort study was 
likely subject to selection bias, because treatment was entirely dependent on the attending 
physician's decision. The PS matching method was applied to balance confounders as much 
as possible; however, because of the limited sample size, few variables were available for 
extensive adjustment using PS matching. The Cox regression models were then constructed to 
adjust for baseline confounders to reduce residual confounders as much as possible, although 
we could not rule out potential unmeasured confounders. Fourth, AF-specific information 
was limited, as AF diagnosis was based on electrocardiography at admission or during 
hospitalization; this may have led to an underestimation of AF. Finally, the purpose of this 
study was to evaluate whether BB therapy at discharge has prognostic implications. Treatment 
with BB was defined at discharge and the likely crossover throughout the follow-up; hence, 
this might have interfered with the potential associations with outcomes (Supplementary Fig. 
3). Moreover, BB-untreated patients may have been at a higher risk due to past intolerance 
or perceived risk of future intolerance. With decreasing numbers of patients at risk and 
increasing crossover patients over time, findings at longer durations of follow-up should be 
interpreted with caution and may underestimate benefits associated with BB use.
In conclusion, the use of BBs at discharge was not associated with clinical outcomes at the 
60-day and 1-year follow-ups in real-world hospitalized patients with HFrEF and AF. In HFpEF 
with AF, BB was only associated with lower incidence of rehospitalization at the 6-month 
and 1-year follow up. Further investigations are required for the development of optimal 
therapeutic options for this patient subgroup.
SUPPLEMENTARY MATERIALS
Supplementary Table 1
Medical therapy at discharge in patients with heart failure with reduced ejection fraction with 
atrial fibrillation
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Supplementary Table 2
Medical therapy at discharge in patients with heart failure with preserved ejection fraction 
and atrial fibrillation
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Supplementary Table 3
Changes of pulse rate and blood pressure in matched cohort during follow up
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Supplementary Table 4
Clinical outcomes in patients with heart failure with reduced ejection fraction with atrial 
fibrillation
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Supplementary Table 5
Multivariate adjusted risk-adjusted beta blocker-outcome link including digoxin and 
amiodarone at discharge
Click here to view
Supplementary Table 6
Clinical outcomes in patients with heart failure with preserved ejection fraction with atrial 
fibrillation
Click here to view
Supplementary Fig. 1
The subgroup in heart failure with reduced ejection fraction. (A) for 1-year rehospitalization 
and (B) for 1-year mortality.
Click here to view
Supplementary Fig. 2
The subgroup in heart failure with preserved ejection fraction. (A) for 1-year rehospitalization 
and (B) for mortality.
Click here to view
Supplementary Fig. 3
Change rate of beta-blocker therapy during follow up.
Click here to view
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